Hereditary angioedema presents with episodic angioedema without urticaria and often with abdominal pain; antihistamines are usually ineffective, the author noted. Researchers randomly allocated 134 adolescents and adults into a double blind crossover trial comparing the oral bradykinin B2 receptor antagonist deucrictibant with placebo during attacks. The study team reported a much shorter median time to onset of symptom relief with deucrictibant—1.28 hours (95% confidence interval 1.05 to 1.52)—compared with a median that exceeded 5.82 hours and extended beyond 12 hours with placebo. The trial outcome suggests a rapid symptomatic benefit during acute attacks. The source did not report longer-term safety or prevention data beyond the crossover attack-treatment episodes.
A study published in the New England Journal of Medicine tested an intravitreal viral vector that delivers a gene to retinal ganglion cells, turning those cells light sensitive. The intervention included patients wearing specialised goggles to translate visual input. The study team observed that six of ten participants achieved a clinically meaningful increase in light sensitivity. The authors were clear that these gains fall short of restoring normal vision; instead, the results demonstrate that retinal cells can be rendered light sensitive by gene delivery, opening further avenues for therapeutic development. The source article did not provide detailed durability data or comparative safety profiles beyond the reported sample results.
Early mechanistic data suggested that boosting levels of nicotinamide riboside, a vitamin B3–related compound, could enhance mitochondrial function and reduce oxidative neuronal injury. A phase 3 oral trial compared nicotinamide riboside with placebo in people with early Parkinson’s disease. Contrary to expectations, the trial investigators found that participants randomised to nicotinamide riboside had worse symptom scores at 52 weeks than those taking placebo; non-motor symptom rates were also higher in the treatment group. The study team concluded there was no clinical benefit and the source did not report mechanistic subgroup explanations or protocol amendments that might explain harm.
Incidental ultrasound reports of fatty liver are common in general practice, and the clinical significance of such findings is often unclear without additional investigation, the author observed. A retrospective observational study examined adults with biopsy confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) and compared outcomes between people with lean MASLD (normal body mass index) and those with MASLD and obesity. Data indicated that mortality rates and other clinical outcomes were similar between the lean and obese groups. The investigators reported that the severity of liver fibrosis—rather than BMI category—was the factor most strongly associated with prognosis. The study reinforces that fibrosis staging remains central when assessing risk in MASLD. The source reported the study design as retrospective and observational; it did not provide randomized comparisons or interventional data.
A large-scale study collected self-reported pain from over six million people across 118 countries to map symptom prevalence by age and region. The cohort showed facial pain prevalence at about 2% and back pain prevalence around 40%. Headache prevalence peaked in people’s mid-30s, while back pain prevalence rose steadily with age. Researchers attributed 18.3% of the overall pain burden to three modifiable risk factors: smoking, obesity, and low income. These findings offer clinicians population-level baselines to inform diagnostic reasoning and public health prioritisation; the source did not provide intervention trial data addressing these risk factors within the same study.
Tom Nolan wrote these research highlights and declared no competing interests. The BMJ article was not commissioned and was not externally peer reviewed, as stated in the source. Specific trial protocols, long-term safety data, and detailed subgroup analyses were not supplied in the short research summaries presented here—readers should consult the primary trial publications referenced for full methods and complete datasets.